Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge, (J Neurooncol (2016), 129:389–393, 10.1007/s11060-016-2196-8)

Daniel N. Cagney; Brian M. Alexander; F. Stephen Hodi; Elizabeth I. Buchbinder; Patrick A. Ott; Ayal A. Aizer

ArticleOPEN ACCESS

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge, (J Neurooncol (2016), 129:389–393, 10.1007/s11060-016-2196-8)

Cagney D
Alexander B
Hodi F
et al.

Journal of Neuro-Oncology

DOI: 10.1007/s11060-017-2485-x

0Citations

6Readers

Abstract

The first author’s middle initial was incorrectly captured as part of the surname in the metadata of the original publication.

Cite

CITATION STYLE

APA

Cagney, D. N., Alexander, B. M., Hodi, F. S., Buchbinder, E. I., Ott, P. A., & Aizer, A. A. (2017, May 1). Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge, (J Neurooncol (2016), 129:389–393, 10.1007/s11060-016-2196-8). Journal of Neuro-Oncology. Springer New York LLC. https://doi.org/10.1007/s11060-017-2485-x

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge, (J Neurooncol (2016), 129:389–393, 10.1007/s11060-016-2196-8)

Abstract

Cite

Register to see more suggestions